Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study

INTRODUCTION: Intensive insulin therapy is recommended for the treatment of type 1 diabetes (T1D). Hypoglycaemia and weight gain are the common side effects of insulin treatment and may reduce compliance. In patients with insulin-treated type 2 diabetes, the addition of glucagon-like peptide-1 recep...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ Open
Hlavní autoři: Dejgaard, Thomas Fremming, Knop, Filip Krag, Tarnow, Lise, Frandsen, Christian Seerup, Hansen, Tanja Stenbæk, Almdal, Thomas, Holst, Jens Juul, Madsbad, Sten, Andersen, Henrik Ullits
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2015
Témata:
Diabetes and Endocrinology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4390685/
https://ncbi.nlm.nih.gov/pubmed/25838513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2015-007791
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky